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Genomic sequencing of a dyslexia
susceptibility haplotype encompassing
ROBO1
Satu Massinen1,2, Jingwen Wang3, Krista Laivuori1,2, Andrea Bieder3, Isabel Tapia Paez3, Hong Jiao3 and Juha Kere1,2,3*
Abstract
Background: The DYX5 locus for developmental dyslexia was mapped to chromosome 3 by linkage study of a
large Finnish family, and later, roundabout guidance receptor 1 (ROBO1) was implicated as a candidate gene at
DYX5 with suppressed expression from the segregating rare haplotype. A functional magnetoencephalographic
study of several family members revealed abnormal auditory processing of interaural interaction, supporting a
defect in midline crossing of auditory pathways. In the current study, we have characterized genetic variation
in the broad ROBO1 gene region in the DYX5-linked family, aiming to identify variants that would increase our
understanding of the altered expression of ROBO1.
Methods: We have used a whole genome sequencing strategy on a pooled sample of 19 individuals in combination
with two individually sequenced genomes. The discovered genetic variants were annotated and filtered. Subsequently,
the most interesting variants were functionally tested using relevant methods, including electrophoretic mobility shift
assay (EMSA), luciferase assay, and gene knockdown by lentiviral small hairpin RNA (shRNA) in lymphoblasts.
Results: We found one novel intronic single nucleotide variant (SNV) and three novel intergenic SNVs in the broad
region of ROBO1 that were specific to the dyslexia susceptibility haplotype. Functional testing by EMSA did not support
the binding of transcription factors to three of the SNVs, but one of the SNVs was bound by the LIM homeobox 2
(LHX2) protein, with increased binding affinity for the non-reference allele. Knockdown of LHX2 in lymphoblast cell lines
extracted from subjects from the DYX5-linked family showed decreasing expression of ROBO1, supporting the idea that
LHX2 regulates ROBO1 also in human.
Conclusions: The discovered variants may explain the segregation of dyslexia in this family, but the effect appears
subtle in the experimental settings. Their impact on the developing human brain remains suggestive based on the
association and subtle experimental support.
Keywords: Dyslexia, ROBO1, Whole genome sequencing
Background
Developmental dyslexia (DD), the most common learning
disability, has a neurobiological and partially genetic
etiology. More than 10 genes are considered as candidate
susceptibility genes for DD based on genetic linkage
studies, targeted association studies, chromosomal
translocations, and chromosomal deletions. [1] Recently,
also genome-wide association studies [2–4] as well as
copy-number analysis [5, 6] have suggested novel genetic
variants to confer susceptibility to DD.
In the general population, DD mostly displays a complex
occurrence pattern, although in some rare families
Mendelian (monogenic) inheritance patterns have
been observed. The largest family so far reported to
show simple autosomal dominant segregation for DD
is a Finnish family in which a genetic linkage study
implicated a locus on chromosome 3, named DYX5
[7] (Fig. 1), carrying a 33-Mb susceptibility haplotype for
dyslexia. In neuropsychological tests, the affected family
members had deficits in phonological awareness, verbal
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short-term memory, and rapid naming; most affected fam-
ily members were classified as having severe DD while
some were diagnosed with mild or compensated DD [8].
The DYX5 locus was supported by a genome-wide
scan where quantitative-trait loci (QTL) for DD were
mapped in families from both the UK and USA [9].
Furthermore, in a QTL analysis on American families
with speech–sound disorder (SSD), DYX5 showed link-
age to SSD-related phenotypes, suggesting that the locus
may have pleiotropic effects [10].
The identity of the susceptibility gene in DYX5 was
fortuitously suggested by the chromosome translocation
t(3;8)(p12;q11) in a dyslexic individual unrelated to the
large family with DYX5 segregation. The translocation
breakpoint was fine-mapped to an intron of roundabout
guidance receptor 1 (ROBO1) transcript variant 1
(NM_002941). Gene expression study of ROBO1 in lym-
phoblasts from members of the large linkage family sug-
gested suppressed expression from the rare haplotype
segregating with DD. No such allelic suppression was
observed for neighboring genes. [11] More recently,
ROBO1 was implicated by genetic association study in a
core trait underpinning language acquisition, with a
specific function in supporting a short-term buffer for
arbitrary phonological strings [12]. An independent
family-based analysis on Canadian samples provided
more support for the association of ROBO1 to DD,
with the associated allele also correlating with low
gene expression in brain tissue [13]. Consistent with an
important developmental role of the ROBO1 locus, a 15-
Mb deletion involving ROBO1 and a few neighboring
genes was found in a child with developmental delay [14].
The ROBO1 gene is orthologous to the roundabout
axon guidance receptor regulating midline crossing of
axons in fruit flies [15]. Homozygous Robo1 knockout
mice display a range of defects in axonal pathfinding,
including anomalies in the development of the corpus
callosum and other major axonal projections [16–18].
Although the affected members of the DYX5-linked fam-
ily express ROBO1 at reduced levels instead of lacking
the expression completely, they also show a defect in
axonal pathfinding, more specifically in the axonal crossing
of auditory pathways. This was shown by using magneto-
encephalography to record the cortical responses to
frequency-tagged auditory stimuli; the ipsilateral suppres-
sion of auditory responses (which is dependent of midline
crossing of the auditory pathways) was deficient in the
dyslexic subjects who carried the dyslexia susceptibility
haplotype. Moreover, the extent of this deficit in interaural
interaction correlated with the expression level of ROBO1
in lymphocytes in a dose-dependent manner [19].
The molecular mechanism for the suppressed expres-
sion of ROBO1 from the DD susceptibility haplotype has
remained unknown. The objective of this study was to
characterize variation within the susceptibility haplotype
in order to find variants that might shed light on the
regulatory effects behind the dysregulation of ROBO1.
We used a whole genome sequencing strategy to identify
any rare variants that might affect gene regulation and
tested the identified variants for function.
Methods
Sample selection
The DNA samples from 19 affected individuals sharing
the same haplotype from the DYX5-linked family [7]
were pooled (Fig. 1). The DNA concentrations were
measured using Nanodrop 1000 spectrophotometer
Fig. 1 Pedigree of the DYX5-linked family. Squares denote males and circles females. The 19 affected individuals marked with dots share the
dyslexia susceptibility haplotype [11], and their DNA samples were pooled for sequencing on the Illumina platform. The DNA from the two
affected individuals denoted by arrows was used in the CGI WGS. Circled dots indicate the individuals whose DNA samples were used in the
Sanger sequencing of the exonic SNPs
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(Thermo Scientific), after which an equimolar pooled
solution was prepared.
Out of the 19 individuals, DNA from 2 males, III.12 and
IV.12 (Fig. 1), were also sent to full genome sequencing at
Complete Genomics Inc. (CGI).
Ethics, consent, and permissions
This study was approved by the ethical review board of
the Helsinki University Central Hospital, and informed
consent was obtained from the participants.
Preparation of next-generation sequencing libraries and
whole genome sequencing (WGS)
DNA libraries for sequencing were prepared using TruSeq
DNA kits (Illumina Inc.) according to the manufacturer’s
instructions with the following changes. The protocols
were automated using an MBS 1200 pipetting station
(Nordiag AB). All purification steps and gel-cuts were
replaced by the magnetic bead clean-up methods as previ-
ously described [20, 21]. Whole genome sequencing of
pooled affected individuals was performed on an Illumina
HiSeq 2000 (Illumina Inc.) as paired-end reads to 100 bp.
The clustering was performed on a cBot cluster gen-
eration system using a HiSeq paired-end read cluster
generation kit (Illumina Inc.). The base conversion
was done using OLB v1.9 (Illumina Inc.). Whole gen-
ome sequencing of two dyslexic male individuals was
performed by CGI.
Sequencing read analysis
Illumina sequence reads were aligned to National Center
for Biotechnology Information (NCBI) human reference
genome build 37, with Burrows-Wheeler Aligner (BWA)
version 0.6.1 [22]. We set the threshold of base quality ≥20
for mapping. Genome Analysis Toolkit version 1.3 [23]
was applied for insertion and deletion (INDEL) re-
alignment and base recalibration, and we performed
single nucleotide variant (SNV) and INDEL discovery
in pooled samples using generalized ploidy model
[24]. The reads with mapping quality less than 20
were not used for SNV and small INDEL calling. The
CGI production pipeline mapped original sequence
data to NCBI reference genome build 37 with
Complete Genomics Analysis Tools (CGA™ Tools).
Variant annotation and filtering
ANNOVAR software [25] was used for variant annotation
and filtering. RefSeq, dbSNP 137 and data from 1000
Genomes Project (2012 February data release) [26], 1000
Genomes Project Finnish data, and Finnish population
data from Sequencing Initiative Suomi (SISu) were used
to annotate variants. Moreover, Integrative Genomics
Viewer [27], Ensembl Genome Browser [28], and UCSC
Genome Browser [29] including the Encyclopedia of DNA
Elements (ENCODE) project data [30] were applied for
read and variant visualization.
We filtered the single nucleotide variants based on the
following criteria:
(a)Select variants within the genomic area of the
dyslexia susceptibility haplotype between markers
D3S3039 and D3S3045 on chromosome 3
(bases 73842243–106990161)
(b)Select variants with same genotype in both CGI
samples
(c)Select variants shared in both CGI samples and
Illumina pooled samples
(d) Select heterozygotes
(e)Filter out the variants with minor allele frequency of
Finnish samples in the 1000 Genomes Project [26]
over 5 %
(f ) Include novel variants (i.e., variants not annotated in
dbSNP and/or 1000 Genomes Project [26] and/or SISu)
INDEL filtration was similar to the strategy for single
nucleotide variant, but we kept the INDEL in both Illu-
mina pooled samples and one of the CGI samples. The
identification of structural variation, including copy num-
ber variation, inversion, and translocation, was performed
in the CGI sequencing dataset by CGA Tools. We also
compared the distance between mapped read pairs with
the average insert size of the genomic library from Illu-
mina paired-end sequencing for structural variation detec-
tion in a pooled-sample dataset.
Transcription factor binding prediction
We employed TRANSFAC Public database [31], JASPAR
database [32], UniPROBE database [33], and P-Match
software [34] to predict the transcription factor (TF)
binding sites on the intergenic variants.
Sanger sequencing
To re-sequence the previously reported exonic variants
in ROBO1 [11], the DNA samples from four dyslexic in-
dividuals used for mRNA expression measurement [11]
and one affected sibling (II.12, III.21, IV.11, IV.12, and
IV.13; Fig. 1) were selected. The DNA samples of two
dyslexic individuals sent to CGI were used for insertion
validation, as well as two non-dyslexic family members.
DNA samples from all of the 19 dyslexic individuals
who carry the dyslexia susceptibility haplotype were re-
sequenced to confirm that the novel SNV at position
84674201 (SNV 4 in Table 3) was true and shared by all
19 individuals.
The primers for the amplification and sequencing reac-
tions were designed using Primer3 [35]. All PCR assays
were performed with standard reagent concentrations and
temperature profiles. Sequencing was performed using
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dye-terminator chemistry and automated sequencers
(Applied Biosystems). Primer sequences are available
on request.
Plasmids
The plasmid construct used for LIM homeobox 2
(LHX2)-V5 overexpression, pLenti6.2-LHX2-V5, was
obtained from DNASU plasmid repository [36]. The
GFP-V5 control plasmid, pLenti6/V5-DEST-GFP, was a
kind gift from Dr. Päivi Ojala.
The luciferase constructs were based on the pGL3
promoter backbone (Promega). We cut the vector with
the restriction enzymes NheI and XbaI and ligated the
inserts with matching sticky ends using T4 DNA liga.
The inserts contained 33 bp surrounding and including
the SNV4 C and T alleles, and the additional bases
needed to generate the sticky ends. The insert sequences
are read from the minus strand of the reference se-
quence because also the ROBO1 is encoded on that
strand. The sequences of the inserts were:
C-allele forward: 5′-CGT TCT TAC AAA GTC CCG
TTA ATT AAT ATT GGT GG-3′
C-allele reverse: 5′-CTA GCC ACC AAT ATT AAT
TAA CGG GAC TTT GTA AGA ACG AGC T-3′
T-allele forward: 5′-CGT TCT TAC AAA GTC CCA
TTA ATT AAT ATT GGT GG-3′
T-allele reverse: 5′-CTA GCC ACC AAT ATT AAT
TAA TGG GAC TTT GTA AGA ACG AGC T-3′
Similarly, the 33-bp insert with the alternative alleles
was also inserted into the vector in reverse orientation
(with the sticky end generating extra bases switching
sides of the insert). pGL3 promoter was used as a con-
trol in the luciferase assay.
In LHX2 knockdown in lymphoblast cell lines, we used
the following lentiviral small hairpin RNA (shRNA)
vectors from the The RNAi Consortium shRNA Library
(TRC-Hs1.0): TRCN0000013418, TRCN0000013419,
TRCN0000013420, and TRCN0000013422. As a control
vector, we used the scramble construct SHC002.
Cell cultures
All cell lines were cultured at 37 °C in a humidified
atmosphere of 5 % (v/v) CO2/air. Human Embryonic
Kidney 293 cells (HEK293) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with
GlutaMAX (GIBCO) and 10 % fetal bovine serum (FBS),
100 U/ml penicillin, and 100 μg/ml streptomycin.
EBV-transformed lymphoblast cell lines from the
DYX5-linked family and controls were cultured in
Roswell Park Memorial Institute (RPMI) 1640 medium,
supplemented with 2 mM L-glutamine, 5–15 % FBS, and
50 μg/ml gentamicin.
Nuclear cell lysates
We made nuclear cell lysates overexpressing LHX2-V5
or GFP-V5. HEK293 cell lines were grown on 6-well
plates and transfected with 3.3 μg plasmid DNA per well
using Fugene HD Transfection Reagent (Promega) ac-
cording to the manufacturer’s instructions. Forty-eight
hours after transfections, approximately 6 × 106 cells in
total were collected from transfection reactions combining
multiple wells from the 6-well plates and the nuclear
soluble proteins were extracted using NE-PER Nuclear
and Cytoplasmic Extraction Reagents (Thermo Scientific)
according to the manufacturer’s instructions. The overex-
pression of LHX2-V5 was confirmed on Western blots
using V5 mouse monoclonal antibody (R960, Life Tech-
nologies) (data not shown). The protein concentration of
the nuclear extracts was measured using Pierce BCA
Protein Assay Kit (Thermo Scientific). The nuclear ex-
tracts from retinal pigment epithelium (RPE)-1 cells were
prepared according to Pierce NE-PER Nuclear Protein
Extraction Kit (Thermo Scientific).
Electrophoretic mobility shift assay (EMSA)
The EMSA was performed using LightShift Chemilu-
minescent EMSA Kit (Thermo Scientific) according to
the manufacturer’s instructions. The wild-type or mutant
probes were 5′-end-labeled in forward strands with bio-
tin (Additional file 1 Table S1). The binding reactions
were carried out according to standard protocol, with
2.5–4 μg nuclear lysates per lane. Protein-free biotin-
labeled probes were loaded as negative controls.
In order to examine if LHX2 antibodies would affect
binding reactions, we added 4 + 4 μg of the LHX2 anti-
bodies, (N-20, Santa Cruz Biotechnology, 19342x) and
LHX2 Antibody (C-20, Santa Cruz Biotechnology, sc-
19344x). The validity of the antibodies was confirmed
on a Western blot using LHX2-V5 overexpressing cell
extracts (data not shown). In the competition assays, an
unlabeled “cold probe” (5′-GGT GAT CAG TAA TTG
GCT TCT CCC-3′) was incubated with a 1000-fold
molar excess for 15 min at room temperature before the
addition of the biotinylated probes.
The EMSA was performed according to a standard
protocol. The binding of the probes to nylon membrane
was carried out using a standard 312-nm transilluminator
for 15 min or Trans-Blot SD Semi-Dry electrophoretic
transfer cell (Bio-Rad) at 20 V for 30 min.
Luciferase assay
HEK293 cells were grown on 96-well plates and cotrans-
fected with three plasmids: (1) 162 ng of pGL3 promoter
with inserts or empty pGL3 promoter vector (Promega),
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(2) 6.5 ng of control Renilla vector pRL-TK (Promega),
and (3) 162 ng of LHX2-V5 vector or GFP-V5 vector.
The transfections were done using Fugene HD (Promega)
transfection reagent according to the manufacturer’s
instructions.
The cells were harvested 24 h after transfection, and
the luciferase activity was determined using the Dual-
Luciferase Reporter Assay System (Promega). All data
were normalized to Renilla luciferase.
Knockdown of LHX2 in lymphoblast cell lines
We first screened four lentiviral shRNA constructs
targeted against LHX2. The transduction protocol was as
follows. The cells were seeded on 24-well plates, 1.5 × 105
cells per plate in a volume of 250 μl. Transductions were
performed on the same day using 500 μl virus particles
(titre was about 7 pg/ml) per well and 8 μg/ml polybrene.
The cells were then incubated in a cell incubator at 37 °C
for 10 min, followed by a centrifugation at 2500 rpm for
30 min and incubation at 37 °C for 4 h. After the trans-
duction, the media was changed into regular RPMI media
supplemented with FCS and gentamicin. The cells were
harvested after 24 or 72 h.
RNA extraction from the cells was done using RNeasy
Plus mini kit (Qiagen), and cDNA synthesis was per-
formed using TaqMan® Reverse Transcription Reagents
(Thermo Fisher Scientific). Real-time PCR was done using
the following TaqMan probes: LHX2 (Hs00180351_m1),
ROBO1 (Hs01560560_m1), glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, 4310884E), and 18S ribosomal
RNA (rRNA, 4310893E) (Thermo Fisher Scientific). The
data were analyzed using the comparative threshold cycle
(Ct) method. The Ct values were normalized against the
geometric mean of GAPDH and 18S rRNA. The normal-
ized Ct values (ΔCt) of the samples with scramble control
shRNA were subtracted from the ΔCt of the shRNA con-
structs targeted against LHX2, resulting in ΔΔCt values.
The fold change was 2−ΔΔCt.
Results
Sequence analysis
Because the dyslexia susceptibility haplotype is large
(33 Mb) and the known variants in the ROBO1 area
were not unique to the DYX5-linked family [11], we
used whole genome sequencing (WGS) to characterize
all genetic variation in the genomic area within the sus-
ceptibility haplotype surrounding ROBO1. We combined
individual- and pooled-sample sequencing strategies; we
sequenced the whole genomes of two affected individuals
at Complete Genomics Inc. (CGI) and used Illumina se-
quencing on a pooled sample including an equal amount
of DNA from all the 19 affected members carrying the
susceptibility haplotype. The pooling strategy allowed us
to unambiguously reconstruct the susceptibility haplotype
as it was shared by all samples in the pool, whereas
the other haplotypes were different, coming from dif-
ferent parents.
In the whole genome sequencing of two individuals
performed at CGI, 97 % of the genome was covered in
both individuals and over 80 % of the genome contained
at least 30-fold reads. The average read depths of two in-
dividual samples were 51-fold and 55-fold. Coverage and
read depth of the ROBO1 region from the CGI dataset
was over 50-fold. We obtained about 1058 million reads
from the WGS of pooled samples by using Illumina plat-
form, and over 92 % of them could be mapped to human
reference genome build 37. After filtering out the PCR
duplicates, we had 598 million mapped reads covering
91 % of the human genome. Pooled-sample sequencing
on Illumina covered 12 % of the human genome over
30-fold (Table 1), and the average read depth was 19-
fold. The whole ROBO1 gene region was covered in
Illumina sequencing mapped reads with an average
depth of 24-fold including over 99.9 % of the 1-Mb
upstream region.
Variant identification and validation
The majority of human genetic variation that is involved
in the cis-acting regulation of transcription is located
within 1 kb of the transcription start site, although the
regulatory variation can extend at least 1 Mb upstream
and downstream from the transcription start site [37].
Therefore, we chose to focus our variant identification
in the genomic area that contains the introns and exons of
the ROBO1 gene and 1 Mb upstream from the promoter.
We searched for single nucleotide variants (SNVs), small
insertions and deletions (INDELs), and large structural
variations (SVs). The two affected individuals sequenced
at CGI shared 619 SNVs in the area of the ROBO1 gene
and 883 in the segment 1 Mb upstream. From the Illu-
mina pooled sequencing data, we found 1276 SNVs in
ROBO1 and 1714 SNVs within 1 Mb upstream of ROBO1.
To exclude false positive results, we compared the variant
datasets between the two platforms. There were in total
597 intronic SNVs, 1 5′UTR SNV, and 852 intergenic
SNVs in the 1-Mb upstream region shared in both
platforms (Table 2). We did not detect any SNVs in the
ROBO1 coding regions.
Table 1 Read depth comparison between the CGI and Illumina
platforms
CGI sample 1 (%) CGI sample 2 (%) Illumina pool (%)
Read depth ≥5× 99.30 99.20 90.10
Read depth ≥10× 98.30 98 85.66
Read depth ≥20× 94.70 93 51.22
Read depth ≥30× 88.40 84.40 12.06
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We excluded homozygous SNVs, because the Finnish
DYX5-linked family shows an autosomal dominant inher-
itance pattern [7]. After filtering, 288 intronic heterozygous
variants and 374 upstream intergenic heterozygous variants
were further annotated according to the 1000 Genomes
Project. We found 14 intronic and 20 upstream variants
with minor allele frequency (MAF) less than or equal to
5 % in all populations. We filtered the data further by com-
paring to the Finnish samples in the 1000 Genomes Project.
It appeared that many variants had a substantially higher
MAF in the Finnish population, which we subsequently ex-
cluded as population-enriched variants. Combining the fil-
tering and annotation information, there were finally one
novel intronic SNV and two novel intergenic SNVs within
1 Mb upstream left for further investigation (Table 3).
The intronic SNV (SNV1) was located between the first
non-coding exon and the first coding exon of the brain-
specific ROBO1a (GenBank:NM_002941.3) splice variant,
i.e., upstream of the ROBO1b (GenBank:NM_133631.3)
variant. The intergenic SNVs (SNV2, SNV3) were 94 and
196 kb upstream of the first ROBO1a exon. Several tran-
scription factors (TFs) were predicted to bind to the sites
containing the three novel SNVs, and the variants might
affect the binding of the TFs. Moreover, SNV1 was located
in an enhancer region according to the FANTOM5 pro-
moterome atlas [38]. However, electrophoretic mobility
shift assay (EMSA) analyses using RPE-1 cell nuclear ex-
tracts did not support TF binding to SNV1, SNV2, or
SNV3 (data not shown).
Because regulatory regions can have long-range effects
on gene promoters, even from distances over 1 Mb [39],
and because SNVs that regulate gene expression have
been shown to be enriched in the area covering 5 Mb
from the transcription start site [40], we extended our
search region to 5 Mb upstream of the ROBO1 promoter
region (Additional file 2 Table S2). We found a novel
SNV (SNV4 in Table 3) 4.8 Mb upstream situated in a
conserved regulatory element identified by comparing
the genomes of 29 mammals [41]. We confirmed the
variant in 19 affected individuals by Sanger sequencing.
We found two insertions in 3′UTR region of ROBO1,
which are SNP rs35691197 and rs113692951, in agreement
with a previous result [11]. Among 242 small INDELs in
ROBO1 intronic and 1-Mb upstream region, 4 deletions
and 34 insertions were novel but they were located in
mononucleotide or dinucleotide repeat regions. One- to 2-
bp INDELs in a repeat region are unlikely to have func-
tional consequences if they appear as typical microsatellite
repeats. After comparison to the Finnish samples in the
1000 Genomes Project, no other variants appeared func-
tionally interesting.
Both individually sequenced samples showed a long
deletion (rs6147914) between ROBO1 exons 3 and 4 and
could be confirmed by junction sequences also in Illu-
mina pooled samples. This 300-bp deletion is, however,
a common structural variation in different populations
and thus unlikely to associate with the suppressed ex-
pression of ROBO1. A 1600-bp deletion together with an
inversion was located at 250 kb upstream of ROBO1.
This deletion was found in many Finnish samples in the
1000 Genomes Project, and in addition, we observed an
inversion linked with the deletion, which shows similar
but not identical inversion patterns as other 1000 Ge-
nomes Project samples. We then extended the searching
region to 5 Mb upstream and found a 457-bp inversion
in 2.4 Mb upstream of ROBO1 and 400 kb upstream of
GBE1. There was no inversion with such size reported
in public genomic variant databases, and the inversion is
not located in any repeat region. We performed Sanger
sequencing on the inversion region of both CGI sam-
ples, but were not able to validate the inversion in one
of the samples (IV.12), and the other sample (III.12)
showed a homozygous inversion and insertion pattern in
this region. Thus, the inversion was unlikely to be part
of the DD susceptibility haplotype.
Consistent with our observations of assumingly neu-
tral SVs within the genomic area of ROBO1, many SVs
within the locus can also be found in the Database of
Genomic Variants (data not shown) [42]. Their role in
Table 2 SNVs in ROBO1 and 1-Mb upstream region on two






Exonic 0 0 0
Intronic 597 290 1
5′UTR 1 0 0
Upstream (1 Mb) 852 374 3
aVariants showing in both Illumina pooled samples and two CGI individual samples
bNot annotated in dbSNP version 137
Table 3 Four unknown single nucleotide variants in ROBO1 upstream region on chromosome 3. The alternative allele fraction (AAF)
estimate refers to the pooled sample of 19 dyslexic individuals
Code Position Ref Alt Depth AAF Gene region Distance to ROBO1 (bp)
SNV1 79667838 A G 19 0.53 ROBO1 intron +149,221
SNV2 79911063 G T 15 0.60 Intergenic −94,004
SNV3 80013510 T C 15 0.67 Intergenic −196,451
SNV4 84674201 C T 32 0.53 Intergenic −4,857,142
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DD is unclear because information on reading
performance of the individuals is not available.
The 33-Mb dyslexia susceptibility haplotype contains
168 RefSeq genes. In order to study the possible effect of
genes other than ROBO1, we searched the whole suscep-
tibility haplotype for rare (MAF < 5 % in 1000 Genomes
Project [26] or Exome Aggregation Consortium (ExAC),
Cambridge, MA) heterozygous coding SNVs. We found
two rare coding SNVs in zinc finger protein 717
(ZNF717) but found no rare coding SNVs for any other
genes (Additional file 3 Table S3).
Re-sequencing of exonic variants in ROBO1
In ROBO1, there was a discrepancy between the genotype
acquired by whole genome sequencing and our earlier
results [11]. Therefore, we performed Sanger sequencing
in the exons in which SNVs have previously been re-
ported: exon 12, exon 18 (NM_002941.2), and 3′UTR
(NM_133631) [11]. We found 6923T>G (rs7616243) in
one affected individual and insertion DIP6203-6205
(rs113692951) in five affected individuals, but all of the
rest of the previously reported exonic SNVs (1741G>A,
2974C>A, 6227C>A, 6483T>A, 6651T>A) were homozy-
gous for the reference allele, and thus, we were not able to
verify them as true variants [11]. The insertion
rs35691197 (not reported in the previous study [11]) was
validated in five affected individuals by Sanger sequencing.
ROBO1 expression
As our previous results for suppressed expression par-
tially depended on the coding but unconfirmed variants,
we proceeded to reconfirm if ROBO1 gene expression
correlates with the DD phenotype in the DYX5-linked
family. We used the total gene expression values for
ROBO1 measured from lymphocytes [19] and compared
them to the phenotypic test results of phonological
awareness in the same individuals [8]. Overall, we con-
firmed that lower ROBO1 expression correlated with
more problems in phonological coding (Fig. 2).
LHX2 binding site analysis
SNV4 was situated in close proximity to a TAATTA
element, which is a high-affinity binding site for homeo-
box transcription factors [43, 44]. LIM homeobox 2
(Lhx2) is a known negative regulator of the expression
of Robo1 in mice [45]. The genomic area of SNV4 was
predicted to bind several transcription factors, including
LHX2 in the UniPROBE database [33]. The T allele was
predicted to create two more overlapping 8-mer binding
sites for LHX2 [44] when compared to the C allele
(Fig. 3), suggesting enhanced binding properties. More-
over, for those positions where there were predicted
binding sites for both alleles, the enrichment scores indi-
cating the binding affinity were slightly higher for the T
allele. This led us to hypothesize that (1) LHX2 may
bind to the genomic area of the SNV4 and that (2)
LHX2 may have higher affinity for the T allele and
possibly explain the suppressed transcription.
Electrophoretic mobility shift assay
We tested the binding of LHX2 to the area of SNV4 by
overexpressing LHX2 in HEK293 cell culture and using
the nuclear protein extracts in EMSA. We tested the
binding of LHX2 to our 33-bp probe including and sur-
rounding SNV4. We detected enhanced binding affinity
of our probes, the 33 bp including and surrounding
SNV4 in the LHX2 overexpressing extracts compared to
control extracts, confirming the binding of LHX2 to this
site. Both of the allelic probes C and T bound LHX2
(Fig. 4). We also tested if we could alter the binding by
adding antibodies that bind to LHX2. We did not detect
Fig. 2 ROBO1 expression and phenotype. The results from phonological
coding tests were scored according to z-point comparisons to control
group mean values, such that the larger the score, the more problems
the subject had in phonological coding. The test scoring was 0 (z≥
−1.0), 1 (−2.0≤ z<−1.0), 2 (−3.0≤ z <−2.0), or 3 (z<−3.0) [8]. The ROBO1
gene expression was measured by real-time PCR from lymphocytes from
the same subjects with higher values indicating higher expression [19].
Blue diamonds denote males and red diamonds females. The plotted
values show a tendency for negative correlation, supporting the idea
that the less ROBO1 is expressed, the more deficit there is in
phonological awareness
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a supershift, but instead, the binding of LHX2 to the
probes was weakened when the antibodies were added,
suggesting that the probes and the antibodies might
compete in binding to the same site in the LHX2 protein
and the addition of the antibodies hampered binding of
the probe to LHX2. As a control, the addition of LHX2
antibodies to the green fluorescent protein (GFP) sample
did not alter the binding of the probes (data not shown).
Furthermore, we tested if we could compete the binding
of the probe by LHX2 by adding an unlabeled cold probe
containing a sequence from the CYP19A1 gene promoter
that is known to bind LHX2 [46]. We observed that the
cold probe did weaken the binding of our probe to LHX2
and that the SNV T was more resistant to the cold probe,
suggesting that LHX2 may have higher affinity for the T
probe than for the C probe. The binding of LHX2 was the
least when both the competing probe and the LHX2 anti-
bodies were added (Fig. 4). We obtained similar results in
three independent EMSA assays.
Luciferase assays
We next studied whether SNV4 would bind to LHX2
also in cell line models. We cloned the same sequences
that were used as probes in EMSA as inserts in lucifer-
ase vectors. In the LHX2 overexpressing cell lines, we
were able to detect increased luciferase promoter activity
of the insert containing vectors when compared to the
control empty vector (P < 0.05 on Student’s t test; Fig. 5).
This happened also when GFP was expressed as a control
(data not shown). This may mean that there are some en-
dogenous factors that bind to the inserts (similarly as
there were protein-DNA complexes and the EMSA assays
in the sample with GFP-V5 overexpression; Fig. 4). In this
assay, we were not able to detect a difference between the
SNVs (Fig. 5). Moreover, we also tested the inserts in re-
verse orientation, but this did not have a significant effect
on luciferase expression (data not shown). The experiment
was repeated three times with similar results.
Knockdown of LHX2 in lymphoblasts
As Lhx2 has been shown to regulate Robo1 in mice
[45], we were interested to see whether the knockdown
of human LHX2 by using lentiviral shRNA vectors
would affect ROBO1 expression in lymphoblast cell
lines. We first screened four constructs from the TCR1
library, and chose the one that gave the best reduction
of LHX2 expression levels measured by real-time PCR,
Fig. 3 Predicted 8-mer binding sites for LHX2 in the genomic area
of SNV4. The reference sequence (shown on the top row) was
scanned for 8-mer binding profiles for transcription factors from the
UniPROBE database [33]. The rows below the reference sequence
show predicted 8-mer binding sites for LHX2, so that the bases that
are not included in the 8-mer are shown in grey. The enrichment
scores from the protein binding microarray data are shown rightmost
on each row. The TAATTA consensus site for homeobox is shown in
green, and the reference allele (cytosine) at SNV4 is shown in red. The
alternative allele (thymidine) is shown in blue
Fig. 4 EMSA for SNV4. Nuclear extracts from HEK293 cells
overexpressing LHX2-V5 or GFP-V5 were used. The arrow shows the
location of the bands that showed differences in the amount of
probe bound in a protein-DNA complex. A mixture of two antibodies
against LHX2 was used to confirm that the protein-DNA complex at
the level indicated by the arrow contains LHX2. An unlabeled probe
was used to compete the binding of LHX2 to the SNV probes. The T
allele seemed to be more resistant than the C allele to the competing
probe as seen when comparing the bands above the asterisks
Fig. 5 Luciferase assay for SNV4. The SNV4-containing pGL3-promoter
vectors were tested for transcriptional activity in HEK293 cells by using
luciferase assays. When combined as a group, the SNV4-containing
vectors showed increased luciferase promoter activity when compared
to the control empty vector (P < 0.05 on Student’s t test). We did not
detect a significant difference between the C and G alleles. The error
bars indicate standard deviation
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which was on average 50 % of the LHX2 expression
levels in cells treated with scrambled shRNA. Next, we
silenced LHX2 in lymphoblast cell lines from individ-
uals from the DYX5-linked family and control cell lines.
We noted that ROBO1 expression was reduced with
downregulated LHX2 expression, suggesting a regula-
tory effect of LHX2 also in humans (Fig. 6a). We ob-
tained similar results in two independent experiments.
ROBO1 and LHX2 expression in the human brain
Our finding that LHX2 knockdown in lymphoblast cells
downregulated ROBO1 expression was surprising in dir-
ection, as in mice Lhx2 has been found to be a negative
regulator of Robo1 [45]. Therefore, we used database in-
formation from the FANTOM5 database [47] to assess
the expression pattern of ROBO1 and LHX2 in different
human brain regions.
The correlation between ROBO1 and LHX2 in both
fetal and adult human brain tissues indicated that the
regulatory effect of LHX2 on ROBO1 expression may
also be positive, suggesting cellular context-dependent
complex regulation (Fig. 6b).
Discussion
The combination of Illumina and CGI whole genome
sequencing enabled us to characterize genetic variation
in a large family with a weakly expressing haplotype of
ROBO1 gene and exclude variants unrelated to the
shared haplotype. The average read depth of Illumina se-
quencing was 19-fold. If the pooled samples were distrib-
uted evenly, there was only a onefold coverage for each
individual. Since we expected to identify a shared
haplotype in all pooled samples, the low coverage per
sample should not affect the detection of the susceptibility
variants. However, at low sequencing depth, the SNV call-
ing program would regard technical errors as variants and
yield false positive results. Nevertheless, the CGI individ-
ual sequencing data, with over 50-fold average depth,
compensated the weakness of low depth in Illumina
sequencing. By comparing the variants between two indi-
viduals, we could exclude the variants with different geno-
types and homozygous variants. After combining Illumina
and CGI data, we excluded half of ROBO1 SNVs detected
from pooled samples. Those variants could be technical
errors generated by Illumina platform or variants that
were not shared by all affected individuals. There were
variants found in CGI data but not detected by pooled se-
quencing. The lower coverage in pooled DNA sequencing
is a potential risk factor for missing variants. However,
some of them were located in well-covered regions, while
the minor alleles only had less than 5× reads. Those vari-
ants might also only appear in those two individuals, but
not in the shared haplotype linked to dyslexia. Technical
errors in the CGI data interpretations might also mislead
analyses. The filtering strategy requiring consistency
across platforms greatly reduced the total number of can-
didate variants and might have resulted in filtering out
true variants.
We used two different WGS sequencing platforms and
Sanger sequencing but were unable to replicate previous
findings on exonic SNVs [11], suggesting that they rep-
resent sequencing artifacts. Nevertheless, the hypothesis
of the reduced expression was supported by the finding
that ROBO1 expression correlated with a measurable
Fig. 6 Correlation between ROBO1 and LHX2 expression. a LHX2 was knocked down by lentiviral shRNA constructs in lymphoblast cell lines
extracted from the DYX5-linked family and from control individuals. Expression levels of LHX2 and ROBO1 were measured by quantitative real-time
PCR. The fold-change values indicate the difference between LHX2-shRNA and the control scramble shRNA-treated cells. Blue indicates the
DYX5-linked family and red indicates controls. The regression lines show that low expression of LHX2 correlates with low expression of ROBO1.
b ROBO1 and LHX2 expression in 22 different brain tissues from the FANTOM5 database. The red dots and lines show the co-expression between
LHX2 and ROBO1 shorter splice variant b. The blue dots and lines show the co-expression between LHX2 and ROBO1 longer splice variant a
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deficit in the crossing of auditory pathways in a dose-
dependent manner [19] and that the lower expression of
ROBO1 associated with a more severe deficit in phono-
logical coding (Fig. 2).
We found a new SNV at position 84674201 situated
near a possible binding site for homeobox transcription
factors (Fig. 3). We were able to show that the transcrip-
tion factor LHX2, previously implicated in regulating
Robo1 in the mouse, has a higher affinity for the non-
reference T allele. Also, luciferase experiments showed
that transcription factors bind to both the reference C
allele and the alternative T allele, but most probably, the
luciferase assay was not sensitive enough to observe any
differences between the two alleles. In the EMSA assay,
the differences between the probes were detectable when
a competing probe was used. We also found that when
LHX2 was knocked down in lymphoblast cell lines, there
was a correlation between the expression of ROBO1 and
LHX2. In support of this finding and adding relevance to
brain development, we observed that ROBO1 and LHX2
have a positive correlation in expression during human
brain development, suggesting complex, possibly cellular
context-dependent regulation.
In mice, Lhx2 is involved in the development of thala-
mocortical connections by regulating Robo1 expression.
Specific conditional deletion of Lhx2 in the thalamus al-
ters projections from the medial geniculate nucleus [45].
This fits well with the previous findings of ROBO1 regu-
lating the crossing of the auditory pathways [19], be-
cause the medial geniculate nucleus is the area in the
thalamus from which the auditory pathways connect to
the auditory cortex [48]. Thus, altered LHX2 binding is
an attractive explanation for the etiology of dyslexia in
the DYX5-linked family. Moreover, an unusual pattern
of cell-size distribution within the medial geniculate nu-
cleus [49] and abnormal thalamo-cortical connectivity
have been observed in subjects with DD [50].
We characterized variation within a susceptibility
haplotype for DD and found several novel variants, but
at first glance, none of them stroke as a severe enough
mutation to be a causative factor for DD with an appar-
ent dominant effect in a large family. One of the pitfalls
is the possible functional role of SNV1, SNV2, and
SNV3. Our EMSA result that did not support the bind-
ing of nuclear factors to the common or variant se-
quences cannot be interpreted to exclude any functional
effects in the developing brain. It is possible but less
likely that we may have missed some variants despite
our sequencing efforts, because the sequence coverage
did not reach 100 %. It is also possible that we may have
discarded a causative variant in our filtering steps that
required consistency.
As a whole the 33-Mb dyslexia susceptibility haplotype
contains roughly 1 % of the human genome, including
168 RefSeq genes. Interestingly, another member of the
roundabout gene family, roundabout guidance receptor
2 (ROBO2), is located near ROBO1 in a head-to-head
orientation within the dyslexia susceptibility haplotype.
Recently, a common variant near the 3′ end of ROBO2
was associated with expressive vocabulary during the
early phase of language acquisition [51]. Moreover, in-
tronic deletions in ROBO2 have been found in two inde-
pendent cases with autism-spectrum disorders [52]. The
Robo1 and Robo2 genes co-operate in axon guidance in
mice during brain development [17] It is likely that also
human ROBO1 and ROBO2 co-operate, and thus,
ROBO2 might contribute to the DD phenotype in the
DYX5-linkage family. However, we did not find any
novel coding variants within the ROBO2 gene.
The expression pattern of ROBO1 with multiple
promoters and differential expression during develop-
ment indicated that the regulation of ROBO1 is likely
to be complex. The experimental models available are
most likely poor proxies of the molecular mechanisms
during brain development, and in reality, very small
effects on the experimental systems may well corres-
pond to major effects during development. Therefore,
any of the new variants discovered in the dyslexia
susceptibility haplotype may be of functional relevance to
explain the reduced expression of the ROBO1 gene.
Conclusions
We have characterized genetic variation in the area of a
dyslexia susceptibility haplotype. Based on our data,
despite the relatively large distance from the ROBO1
promoter region, one SNV was implicated as a possible
causal variant, even though the role of other discovered
variants cannot be excluded.
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